Detalles de la búsqueda
1.
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Lung Cancer (Auckl)
; 14: 63-69, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37383584
2.
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Lung Cancer (Auckl)
; 14: 101-109, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38111829
3.
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting.
Lung Cancer (Auckl)
; 14: 57-62, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37377783
4.
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia.
Lung Cancer (Auckl)
; 14: 71-78, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37440867
Resultados
1 -
4
de 4
1
Próxima >
>>